However, resistance to these TKIs develops in significant portions of patients under treatment, especially in those with CML in advanced stages or with Ph+ ALL, mostly due to the emergence of mutations in the BCR/ABL kinase domain. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.